Wassim Abida, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses whether he would recommend FDA-approved PARP inhibitors (ie, olaparib, rucaparib) in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring alterations in homologous recombination repair (HRR) genes other than BRCA1/2. In the pivotal PROFOUND trial of olaparib in mCRPC, researchers examined PARP inhibition in patients with at least 1 of 15 different genes with a direct or indirect role in HRR: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L. In the video, Abida explains how the specific mutation type determines whether or not he feels comfortable recommending a PARP inhibitor for a patient.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Agents show potential to bolster precision medicine in prostate cancer
March 12th 2024"[Now that] we have entered the era of precision and personalized medicine, well-designed clinical trials are needed to address selected focused questions regarding optimal therapy sequencing,” says Maha H.A. Hussain, MBChB.